Oct 06, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Tarsus Pharmaceuticals ( TARS ) Moves 10.9% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Oct 03, 2025 • Benzinga
SOMEWHAT-BULLISH
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units ...
Oct 01, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Arcutis Biotherapeutics, Inc. ( ARQT ) Hit a 52 Week High, Can the Run Continue?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sep 29, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Are Medical Stocks Lagging Arcutis Biotherapeutics ( ARQT ) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Sep 25, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Here's Why Arcutis Biotherapeutics, Inc. ( ARQT ) is a Great Momentum Stock to Buy
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sep 17, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Arcutis To Present Multiple New ZORYVE® ( roflumilast ) Data Analyses at European Academy of Dermatology and Venereology Congress
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress ...